Kymera Therapeutics (KYMR) Study Result summary

Immunology strategy and rationale for STAT6 targeting

• STAT6 is a key transcription factor downstream of IL-4/IL-13, validated by human genetics and clinical data, with dupilumab as a benchmark therapy.

• Oral STAT6 degraders aim to match or surpass biologics' efficacy with the convenience of oral dosing, addressing a large unmet need in Th2 diseases.

• Targeted protein degradation enables continuous pathway blockade, overcoming limitations of traditional small molecules.

• The immunology market is large and underserved, with only 3% of patients on advanced systemic therapies; oral options could address significant unmet need.

• STAT6 is a highly validated target with strong genetic and clinical rationale; oral degraders like KT-621 could expand access to advanced therapies for millions currently not served by injectables.

Study design and objectives

• Phase 1 trial was randomized, double-blind, placebo-controlled, enrolling 118 healthy volunteers in single and multiple ascending dose cohorts.

• Primary objectives included safety, tolerability, pharmacokinetics, STAT6 degradation in blood and skin, and Th2 biomarker modulation.

• Doses ranged from 1.5 mg to 800 mg, with 70–118 subjects enrolled across cohorts.

• Exploratory endpoints included STAT6 protein levels in blood and skin, and Th2 biomarker changes.

• The study included both single (SAD) and multiple ascending dose (MAD) cohorts.

Pharmacokinetics

• KT-621 showed rapid absorption (median Tmax 2–4 hours) and a mean half-life of 9–36 hours.

• Dose-proportional increase in exposure and steady-state achieved by Day 4.